Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b/2a Multidose Safety and Tolerability Study of Liposomal Amikacin for Inhalation (Arikayce™) in Cystic Fibrosis Patient With Chronic Infections Due to Pseudomonas Aeruginosa.

NCT00558844 is registered in ClinicalTrials.gov with Insmed Incorporated as lead sponsor.

NCT NCT00558844
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00558844 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b/2a Multidose Safety and Tolerability Study of Liposomal Amikacin for Inhalation (Arikayce™) in Cystic Fibrosis Patient With Chronic Infections Due to Pseudomonas Aeruginosa.
Lead sponsor
Insmed Incorporated
Phase
Phase 1/2
Overall status
Completed
Start date
January 31, 2008
Completion date
June 30, 2009
Enrollment
41 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

cystic fibrosis